Blueprint Medicines Corp. (NASDAQ:BPMC) shares rose 2.7% during trading on Friday . The stock traded as high as $27.50 and last traded at $27.33, with a volume of 100,815 shares changing hands. The stock had previously closed at $26.60.

BPMC has been the subject of several research reports. Zacks Investment Research raised shares of Blueprint Medicines Corp. from a “hold” rating to a “buy” rating and set a $27.00 price objective for the company in a report on Thursday, August 11th. Cowen and Company reissued a “buy” rating on shares of Blueprint Medicines Corp. in a report on Tuesday, August 9th. Canaccord Genuity initiated coverage on shares of Blueprint Medicines Corp. in a report on Friday, August 5th. They set a “buy” rating and a $26.00 price objective for the company. TheStreet raised shares of Blueprint Medicines Corp. from a “sell” rating to a “hold” rating in a report on Friday, July 29th. Finally, Wedbush reissued an “outperform” rating and set a $41.00 price objective on shares of Blueprint Medicines Corp. in a report on Tuesday, August 9th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $29.43.

The company’s 50-day moving average price is $22.24 and its 200 day moving average price is $18.78. The firm’s market capitalization is $738.12 million.

Blueprint Medicines Corp. (NASDAQ:BPMC) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.03. The firm earned $7.07 million during the quarter, compared to analysts’ expectations of $4.41 million. The firm’s quarterly revenue was up 163.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.81) EPS. On average, analysts expect that Blueprint Medicines Corp. will post ($3.05) earnings per share for the current year.

In other Blueprint Medicines Corp. news, CEO Jeffrey W. Albers sold 17,000 shares of Blueprint Medicines Corp. stock in a transaction on Monday, August 8th. The shares were sold at an average price of $22.86, for a total value of $388,620.00. Following the completion of the transaction, the chief executive officer now owns 76,494 shares of the company’s stock, valued at $1,748,652.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

A hedge fund recently raised its stake in Blueprint Medicines Corp. stock. RS Investment Management Co. LLC boosted its position in shares of Blueprint Medicines Corp. (NASDAQ:BPMC) by 17.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 740,310 shares of the company’s stock after buying an additional 109,878 shares during the period. RS Investment Management Co. LLC owned about 2.73% of Blueprint Medicines Corp. worth $19,500,000 at the end of the most recent reporting period.

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.